Masimo Corporation Unveils Next-Gen Root Monitor; Can Its Innovations Help Grap A Larger Pie Of The Market?

Masimo Corporation’s second quarter of 2025 presents a mixed yet interesting picture for potential investors, focusing predominantly on the healthcare technology sector while strategizing significant organizational and operational shifts. The quarter reflected growth in core areas but faced challenges in others, encapsulated by both strategic initiatives and external disruptions. On the positive side, Masimo reported continued strength in its healthcare business, with revenue reaching $370 million, marking a 7.4% increase on a constant currency basis. The company achieved an earnings per share (EPS) of $1.33, showcasing a 46% growth from the previous year. This growth was supported by operational improvements translating into a 600 basis point expansion in operating margins, attributed to last year’s cost structure actions. Furthermore, Masimo made strides in tariff mitigation, cutting anticipated impacts by over 50%, thanks to supply chain adjustments and USMCA exemptions.